香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院質子治療中心（以下簡稱「廣州 醫院質子中心」）自2024年12月16日起至今，已正式運營一周年。公司高度重視 質子治療中心的臨床能力建設，堅持加強與國際先進醫療機構合作科研，與國際 質子治療技術同步發展，通過引進高端醫療人才、加強技術研發與學術交流等方 式，持續提升診療水平。截至目前，廣州醫院質子中心的臨床服務能力已得到充 分驗證，各項運營指標表現良好。 廣州醫院質子中心四間質子治療室已經全部啟用，累計為550位患者提供質子治 療服務，單月新增患者超過80人，服務能力持續提升。服務患者範圍覆蓋國內31 個省級行政區以及20多個國家和地區，接受質子治療的患者年齡從1歲至91歲。 2025年7月，廣州醫 ...

Core Viewpoint - The release of the "Clinical Practice Guidelines for Ion Radiation Therapy (2025 Edition)" and the "Quality Assurance Guidelines for Proton Radiation Therapy Systems (2025 Edition)" marks the establishment of systematic and comprehensive industry standards for high-end radiation therapy in China [1][2]. Group 1: Industry Standards and Contributions - The guidelines were developed by a team including experts from Guangzhou Taihe Hospital, part of Meizhong Jiahe Medical Technology Development Group, along with top public institutions [1]. - Meizhong Jiahe has been involved in the formulation of national guidelines four times in recent years, contributing to six national standard outcomes, indicating a shift from occasional participation to a sustained and systematic role in standard-setting [1][2]. - Industry experts view participation in national standard formulation as a certification of technical and quality systems, reflecting long-term accumulation of capabilities [1]. Group 2: Competitive Position and Growth Potential - With stricter regulations and detailed standards, the industry is entering a phase where stronger capabilities lead to faster expansion, benefiting Meizhong Jiahe in approvals, collaborations, academic branding, and clinical appeal [2]. - All four proton therapy rooms at Guangzhou Taihe Hospital are now operational, leading to rapid growth in treatment volume and solidifying its position as a particle center in South China [2]. - Meizhong Jiahe's long-term performance, marked by its four entries into national guidelines and six contributions, positions it among the few social medical entities in the top tier of the industry, enhancing its competitive advantage in high-end radiation therapy [2].

Core Viewpoint - The inclusion of Guangzhou Taihe Cancer Hospital in the "Hong Kong-Macao Drug and Device Pass" list represents a significant breakthrough for the company in accessing international medical resources and enhancing its service capabilities in cancer treatment [1][2]. Group 1: Company Developments - The hospital has successfully passed the approval process to be listed as a designated medical institution under the "Hong Kong-Macao Drug and Device Pass" policy, which facilitates the introduction of innovative drugs and devices approved in Hong Kong and Macao but not yet available in mainland China [1]. - This policy is expected to broaden the legal supply channels for urgently needed clinical treatments, providing policy support for residents in the Greater Bay Area to access advanced medical services in line with international standards [1][2]. - The company has established professional barriers in precision treatment, proton therapy, and multidisciplinary diagnosis and treatment, which will be further strengthened by this new designation [1][3]. Group 2: Industry Implications - The advancement of the "Hong Kong-Macao Drug and Device Pass" not only enhances the service capabilities of individual institutions but also contributes to the construction of a high-level medical service network characterized by tiered diagnosis and regional collaboration [2]. - Designated medical institutions can attract patients from surrounding areas by introducing international innovative drugs and devices, gradually forming regional cancer treatment centers and optimizing the allocation of medical resources [2]. - The ongoing release of policy dividends in the Greater Bay Area is expected to accelerate the flow of cross-border medical resources, allowing the company to benefit continuously from its specialized and international strategic layout [2].

Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, positioning itself as a key beneficiary of the policy and providing clear growth opportunities for investors [1][3]. Group 1: Company Developments - The approval allows Guangzhou Taihe Tumor Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1]. - The hospital can now introduce innovative drugs and medical devices in the oncology field, enhancing its competitive advantage and broadening its business scope [1][2]. Group 2: Industry Implications - The "Hong Kong-Macao Drug and Medical Device Access" initiative aims to improve the quality of medical services and align domestic treatments with international standards, particularly in oncology [2][3]. - The initiative is expected to reduce the treatment time gap between mainland China and international markets, particularly for diseases like breast cancer and lung cancer, thereby enhancing patient treatment options [2]. - The increased accessibility of cross-border medical resources will likely attract more patients to hospitals with such capabilities, creating a "regional treatment center" effect and increasing overall service intensity [2][3].

每经AI快讯，美中嘉和(02453.HK)高开逾6%，截至发稿涨6.12%，报2.08港元，成交额10.07万港元。 ...

Core Viewpoint - The stock of Meizhong Jiahe (02453) opened over 6% higher following the approval of its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Pass" designated medical institution list [1] Group 1: Company Developments - Meizhong Jiahe's stock rose by 6.12%, reaching HKD 2.08, with a trading volume of HKD 100,700 [1] - The approval allows Guangzhou Taihe Oncology Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, enhancing its competitive advantage in the oncology field [1] Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Pass" is a key initiative under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] - Designated medical institutions in the Greater Bay Area can leverage special pharmaceutical policies, allowing them to access advanced medical solutions [1] - The initiative aims to broaden the business scope of qualified institutions and provide urgently needed medications to more oncology patients, thereby strengthening the overall competitive landscape in the oncology medical sector [1]

Core Viewpoint - Meizhong Jiahe (02453) has received approval for its subsidiary, Guangzhou Taihe Oncology Hospital, to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its competitive advantage in the oncology field [2][4]. Group 1: Company Developments - Meizhong Jiahe's stock price increased by 8.67%, reaching HKD 2.13, with a trading volume of HKD 664,600 [2][4]. - The approval allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [2][4]. - This qualification positions the company as a specialized oncology medical institution with the capability to introduce innovative drugs and devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [2][4]. Group 2: Industry Context - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key implementation measure of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [2][4]. - The initiative aims to facilitate the use of clinically necessary drugs and advanced medical devices in designated institutions within the Greater Bay Area, enhancing healthcare access for patients [2][4].

Core Viewpoint - Meizhong Jiahe (02453) has seen a significant stock price increase of 6.12%, reaching HKD 2.08, following the announcement of its subsidiary Guangzhou Taihe Oncology Hospital being approved to enter the "Hong Kong-Macao Drug and Medical Device Access" list, enhancing its competitive edge in the oncology sector [1] Group 1 - The approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration allows the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification positions the company as a specialized oncology medical institution with the capability to utilize innovative drugs and medical devices, thereby broadening its business scope and creating a differentiated competitive advantage in the market [1] - The initiative is part of the core implementation measures of the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan," which aims to facilitate the use of clinical urgently needed drugs and advanced medical devices in designated medical institutions [1]

Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1: Regulatory Approval - Guangzhou Taihe Oncology Hospital received approval from the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration on December 8, 2025, to be included in the designated medical institution list for the Guangdong-Hong Kong-Macao Greater Bay Area [1] - The "Hong Kong-Macao Drug and Medical Device Access" initiative is a key measure under the "Guangdong-Hong Kong-Macao Greater Bay Area Drug and Medical Device Regulatory Innovation Development Work Plan" [1] Group 2: Business Expansion - The qualification allows the company to import and use urgently needed drugs and advanced medical devices that have been approved in Hong Kong and Macao but not yet in mainland China [1] - This move will enable the company to introduce innovative oncology drugs and expand its business boundaries, creating a differentiated competitive advantage in the oncology market [1] Group 3: Clinical and Research Enhancement - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, improving clinical diagnosis and treatment levels as well as research capabilities [1] - By introducing cutting-edge medical devices and optimizing oncology treatment plans, the company aims to align with international medical standards and enhance the overall patient service experience and treatment outcomes [1]

Core Viewpoint - The company, Meizhong Jiahe (02453), announced that its subsidiary, Guangzhou Taihe Oncology Hospital, has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, enhancing its capabilities in oncology treatment and competitive advantage in the market [1] Group 1 - The approval was granted by the Guangdong Provincial Health Commission and the Guangdong Provincial Drug Administration, allowing the hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1] - This qualification enables the company to be recognized as a professional oncology medical institution with the capability to utilize innovative drugs and medical devices from Hong Kong and Macao, thereby broadening its business scope [1] - The initiative will facilitate deeper integration with Hong Kong and Macao medical resources, enhancing clinical diagnosis and treatment levels, and accelerating alignment with international medical standards [1] Group 2 - The introduction of cutting-edge drugs and medical devices is expected to optimize oncology treatment plans and improve patient service experience and treatment outcomes [1] - The company aims to provide urgently needed medications for more oncology patients, reinforcing its competitive edge in the oncology medical field [1]